Welcome to our dedicated page for Polypid Ltd. SEC filings (Ticker: PYPD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PolyPid Ltd. (Nasdaq: PYPD) SEC filings page on Stock Titan brings together the company’s regulatory disclosures as a foreign private issuer. PolyPid files annual reports on Form 20-F and frequent Form 6-K current reports, which provide detailed information on its clinical, regulatory, financial and corporate developments as a late-stage biopharma company.
Recent Form 6-K filings incorporate press releases on key milestones for D-PLEX100, PolyPid’s lead product candidate for the prevention of abdominal colorectal surgical site infections. These filings include reports of positive Phase 3 SHIELD II trial results, positive FDA pre-NDA meeting minutes supporting a New Drug Application submission, and the granting of Breakthrough Therapy designation. They also capture updates on the company’s regulatory strategy, such as the FDA’s agreement to a rolling NDA review.
PolyPid’s SEC reports further document manufacturing and quality milestones, including the successful completion of a Good Manufacturing Practice (GMP) inspection by the Israeli Ministry of Health under the EU-Israel ACAA framework, which the company states confirms that its facility meets standards required for commercial production in the European market. Other 6-Ks address corporate governance matters, such as changes in board leadership, executive appointments, shareholder meeting outcomes and compensation policy approvals.
Financial information is regularly furnished through interim condensed consolidated financial statements and management’s discussion and analysis, attached as exhibits to Form 6-K. Additional filings describe capital-raising arrangements, including a Sales Agreement for the issuance and sale of ordinary shares and subsequent increases to the maximum aggregate offering price.
On Stock Titan, these filings are complemented by AI-powered summaries that highlight the main points of each document, helping readers quickly understand the significance of PolyPid’s 20-F annual reports, 6-K current reports and other registered offerings without reading every line of the underlying SEC text.
PolyPid Ltd. provides an annual update centered on D-PLEX100, its lead local, controlled-release antibiotic for preventing surgical site infections after abdominal colorectal surgery. In the pivotal SHIELD II Phase 3 trial, D-PLEX100 plus standard care cut primary endpoint events to 10.9% versus 18.1% with standard care alone, a 40% reduction (p<0.005), and also reduced deep and superficial infections to 3.8% versus 9.5%. The company reports positive FDA pre-NDA meeting minutes and plans a rolling NDA submission beginning by the end of the first quarter of 2026, supported by Fast Track and Breakthrough Therapy designations and EMA centralized-procedure eligibility. Beyond D-PLEX100, PolyPid highlights an early long-acting GLP-1 platform for ~60-day subcutaneous release, the OncoPLEX intra-tumoral chemotherapy candidate, and a new STING-agonist collaboration, while noting it has never generated revenue and expects to need substantial additional funding as a development-stage biopharmaceutical company.
PolyPid Ltd. shareholder filing shows a concentrated institutional position with warrant overhang. Rosalind Advisors Inc., Rosalind Master Fund L.P., and portfolio managers Steven Salamon and Gilad Aharon report beneficial ownership tied to 5,483,443 Common Shares, representing 9.9% of the class based on 18,204,002 shares outstanding as of December 31, 2025.
The filing explains that this figure includes 696,556 Common Shares plus 4,786,887 shares issuable upon warrant exercise. Because the warrants contain a 9.99% beneficial ownership blocker, the reporting persons state they could not exercise the warrants as of the event date and that the advisor and Mr. Salamon disclaim beneficial ownership of shares held by the fund.
PolyPid Ltd. reported wider losses for 2025 while advancing its lead drug D-PLEX₁₀₀ toward potential commercialization. Net loss for 2025 was $34.2 million, compared with $29.0 million in 2024, driven mainly by higher research and development and general and administrative expenses.
Cash and cash equivalents were $6.4 million at December 31, 2025, with short-term deposits of $6.5 million, bringing total current assets to $15.2 million. Shareholders’ equity increased to $11.0 million from $7.7 million, reflecting additional paid-in capital.
The company highlighted successful completion of its Phase 3 SHIELD II trial for D-PLEX₁₀₀, positive FDA pre-NDA feedback supporting a rolling NDA review, and advanced-stage U.S. commercial partnership discussions. PolyPid stated it believes 2026 could mark a transition from late-stage development to full commercial execution.
PolyPid Ltd. held an Extraordinary General Meeting of Shareholders on February 4, 2026, where a quorum was present and shareholders approved Proposal No. 1 as originally proposed. The specific substance of the proposal is not described in this excerpt.
The report states that this 6-K is incorporated by reference into several existing Form F-3 and Form S-8 registration statements, meaning those securities registration documents now also include this shareholder meeting outcome as part of their disclosure record.
PolyPid Ltd. received an amended Schedule 13G showing that investment manager AIGH Capital Management LLC and Orin Hirschman beneficially own 1,793,117 ordinary shares, representing 9.8% of the class. They report sole voting and dispositive power over these shares.
The filing notes that this ownership percentage excludes 2,395,268 common shares issuable upon exercise of warrants that are not currently exercisable due to beneficial ownership limits, and 549,141 shares held in abeyance. The holders state the shares were acquired and are held in the ordinary course of business and not for the purpose of influencing control of PolyPid.
PolyPid Ltd. has appointed Brooke Story as a director and chairman of its Board of Directors, effective December 11, 2025. Story, age 54, is a veteran medtech executive who has led the separation and integration management office at BD since June 2024 and previously served as Worldwide President in multiple BD business units.
Before joining BD, she held senior leadership roles at Medtronic in pelvic health and gastric therapies and has board experience at LivaNova and Sigilon Therapeutics. The Board determined she is independent under Nasdaq rules. Her compensation for Board service will be presented for approval at an upcoming shareholder meeting, and she is expected to enter into PolyPid’s standard indemnification agreement for directors and executive officers.
PolyPid Ltd. filed a Form 6-K to furnish a press release dated December 3, 2025 announcing positive U.S. FDA pre-NDA meeting minutes for its D-PLEX100 product, which support a planned New Drug Application submission. The filing states that the first three paragraphs of the press release and its forward-looking statements section are incorporated by reference into several existing PolyPid shelf and equity compensation registration statements on Forms F-3 and S-8, so that those registration documents now include this updated regulatory information.
PolyPid Ltd. (PYPD) is increasing its at-the-market share offering program to a maximum aggregate offering price of up to $15,000,000 of ordinary shares under its Form F-3 shelf. This prospectus supplement raises the prior cap of $8,250,000 and continues the sales agreement with Oppenheimer & Co. Inc. as sales agent on a best efforts basis. Oppenheimer will receive a 3.0% commission on the gross sales price per share and reimbursement of up to $40,000 of specified expenses.
The company’s ordinary shares trade on Nasdaq under the symbol PYPD; the last reported sale price was $3.68 per share on November 25, 2025. The aggregate market value of ordinary shares held by non-affiliates was $65,953,832 as of October 30, 2025, based on 17,175,477 non-affiliate shares at $3.84 per share.
PolyPid Ltd. (PYPD) reports that on November 26, 2025 it increased the maximum aggregate offering price of its ordinary shares issuable under its Sales Agreement with Oppenheimer & Co. Inc. from
The company also filed a legal opinion from Sullivan & Worcester Tel-Aviv (Har-Even & Co.) as Exhibit 5.1, addressing the legality of issuing and selling these ordinary shares under the Sales Agreement. This report is incorporated by reference into multiple existing PolyPid shelf registration statements on Form F-3 and equity compensation registration statements on Form S-8, so that future share sales under the Sales Agreement can rely on this updated disclosure.
PolyPid Ltd. submitted a Form 6-K to furnish a press release titled “PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results.” The filing notes that the press release includes recent corporate highlights, financial results for the three and nine months ended September 30, 2025, balance sheet highlights and forward-looking statements.
These specific sections of the press release, along with the attached financial statements, are incorporated by reference into multiple existing PolyPid registration statements on Forms F-3 and S-8, so they become part of those offerings from the date of this report, unless later filings supersede them.